Ketamine is an anesthetic drug that is also used for off-label indications such as the
mediation of analgesia and sedation in various settings. It is additionally recognized as an …

Background: Ketamine, administered in subanesthetic doses, is an effective off-label
treatment for severe and even treatment-refractory depression; however, despite dozens of …

This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …

S everal clinical trials have demonstrated the rapid antidepressant effects of the N-methyl-d-
aspartate (NMDA) antagonist ketamine for the treatment of both major depressive disorder …

Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Ketamine, administered in subanesthetic doses, is gaining recognition as an off-label
treatment for severe and even treatment-refractory depression. This article explores potential …

Depression is a well-known serious mental illness, and the onset of treatment using
traditional antidepressants is frequently delayed by several weeks. Moreover, numerous …

Objective: Narrative review of the literature on the efficacy and safety of subanaesthetic
doses of ketamine for the treatment of depression. Method: Medline and PubMed databases …

Major depressive disorder (MDD) is a serious psychiatric illness that causes functional
impairment in many people. While monoaminergic antidepressants have been used to …

The appeal of ketamine–in promptly ameliorating depressive symptoms even in those with
non-response–has led to a dramatic increase in its off-label use. Initial promising results …